AstraZeneca to partner with Eli Lilly on Alzheimer's drug
September 16, 2014 at 02:24 AM EDT
LONDON, Sept 16 (Reuters) - AstraZeneca has struck a partnership deal worth up to $500 million with Eli Lilly for the British group's experimental Alzheimer's drug, which is set to enter late-stage Phase III development.
